Eubiologics' typhoid vaccine receives WHO prequalification, eyes international market

South Korean biotechnology firm Eubiologics announced on August 21 that its self-developed typhoid conjugate vaccine, EuTYPH-C Inj., has successfully obtained prequalification (PQ) from the World Health Organization (WHO).

This significant achievement opens the door for EuTYPH-C Inj. to participate in international procurement tenders organized by global health bodies such as UNICEF. The WHO PQ is a crucial step for vaccines aiming for widespread use in developing countries and inclusion in global immunization programs.

EuTYPH-C Inj. is Eubiologics' second product to receive WHO prequalification. The company previously secured PQ for its oral cholera vaccine, EuCoBi. This track record demonstrates Eubiologics' growing capacity to meet stringent international standards for vaccine development and manufacturing, positioning it as a key player in the global vaccine market.